Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Short-term Investments (2022 - 2025)

LifeStance Health (LFST) has disclosed Short-term Investments for 4 consecutive years, with $489000.0 as the latest value for Q2 2025.

  • Quarterly Short-term Investments fell 86.36% to $489000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $489000.0 through Jun 2025, down 86.36% year-over-year, with the annual reading at $1.3 million for FY2024, N/A changed from the prior year.
  • Short-term Investments for Q2 2025 was $489000.0 at LifeStance Health, down from $847000.0 in the prior quarter.
  • The five-year high for Short-term Investments was $62.6 million in Q2 2023, with the low at $489000.0 in Q2 2025.
  • Average Short-term Investments over 4 years is $13.2 million, with a median of $3.9 million recorded in 2024.
  • The sharpest move saw Short-term Investments surged 37.3% in 2023, then tumbled 94.28% in 2024.
  • Over 4 years, Short-term Investments stood at $4.4 million in 2022, then soared by 33.73% to $5.9 million in 2023, then plummeted by 78.51% to $1.3 million in 2024, then tumbled by 61.56% to $489000.0 in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $489000.0, $847000.0, and $1.3 million for Q2 2025, Q1 2025, and Q4 2024 respectively.